Kerendia i svenska riktlinjer
Kerendia ingår sedan flera år i ledande internationella riktlinjer. Vi har samlat några här.
“Finerenone is recommended in addition to an ACEi or ARB in patients with T2DM and eGFR >60 mL/min/1.73 m2 with a UACR ≥30 mg/mmol (≥300 mg/g), or eGFR 25-60 mL/min/1.73 m2 and UACR ≥3mg/mmol (≥30 mg/g) to reduce CV events and kidney failure”.
"As people with CKD and albuminuria are at increased risk for cardiovascular events and CKD progression, a nonsteroidal mineralocorticoid receptor antagonist that has been shown to be effective in clinical trials is recommended to reduce cardiovascular events and CKD progression (if eGFR is ≥25 mL/min/1.73 m2). Potassium levels should be monitored."
We suggest a nonsteroidal mineralocorticoid receptor antagonist with proven kidney or cardiovascular benefit for patients with T2D, an eGFR ≥25 ml/min per 1.73 m2, normal serum potassium concentration, and albuminuria (≥30 mg/g [≥3 mg/mmol]) despite maximum tolerated dose of RAS inhibitor (RASi).
“A non steroidal MRA (ns-MRA) with proven kidney and CV benefit is recommended for patients with T2D, eGFR ≥25mL/min/1.73 m2, normal serum potassium concentration, and albuminuria (albumin-to-creatinine ratio [ACR] ≥30 mg/g despite maximum tolerated dose of renin-angiotensin system inhibitor (RASi).”